89979-13-5

Basic information

• Product Name: (Chlorosulfonyl)carbaMic Acid Benzyl Ester
• Synonyms: (Chlorosulfonyl)carbaMic Acid Benzyl Ester
• CAS NO: 89979-13-5
• Molecular Formula: C₈H₈ClNO₄S
• Molecular Weight: 249.67142
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals, Sulfur & Selenium Compounds
• Mol File: 89979-13-5.mol
• Article Data: 31

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (Chlorosulfonyl)carbaMic Acid Benzyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: (Chlorosulfonyl)carbaMic Acid Benzyl Ester(89979-13-5)
• EPA Substance Registry System: (Chlorosulfonyl)carbaMic Acid Benzyl Ester(89979-13-5)

Safety Data

• Hazardous Substances Data: 89979-13-5(Hazardous Substances Data)

Usage

Uses

(Chlorosulfonyl)carbamic Acid Benzyl Ester, is used in the synthesis of various pharmaceutical compounds, such as inhibitors.

Upstream product

• 100-51-6 benzyl alcohol 
• 1189-71-5 isocyanate de chlorosulfonyle 

Downstream Products

• 1026742-97-1 C₁₈H₁₇N₃O₅S 

Relevant articles and documents

A novel regio- and stereoselective synthesis of sulfamidates from 1,2-diols using Burgess and related reagents: A facile entry into β-amino alcohols

An increasingly targeted functional motif in organic synthesis is the ubiquitous chiral β-amino alcohol. A novel two-step approach for the regio- and stereo-selective synthesis of a wide variety of 1,2-amino alcohols 4 involves the initial construction of chiral sulfamidates 3 from enantiopure diols 1, mediated by Burgess reagent (2, R = Me), followed by mild treatment with aqueous acid. Furthermore, the development of several new Burgess-type reagents 2 (R = CH2Ph, CH2-o-NO2Ph, CH2CHCH2, CH2CCl3) greatly extends the applications of this protocol.

N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Carbonic Anhydrase Glycoinhibitors belonging to the Aminoxysulfonamide Series

Abstract A general approach for the synthesis of carbonic anhydrases glycoinhibitors belonging to an aminoxysulfonamide series is presented using a Ferrier sulfonamidoglycosylation reaction on glycals. All the compounds showed good in vitro inhibitory activity against four human carbonic anhydrase isoforms, with selectivity against the cytosolic (hCA II) vs the tumor associated (hCA IX and XII) enzymes.